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In their thought-provoking commentary, Levy et al. [1] explore the possible unintended 
consequences of United Kingdom (UK) guideline targets on the high frequency of 
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hypoglycaemia in people with diabetes who are hospitalized. The authors cite the National 
Institute for Health and Care Excellence (NICE) and the Joint British Diabetes Societies (JBDS) 
guidelines pertaining to inpatient, surgical and pregnancy diabetes care. These guidelines suggest 
using lower limits of glucose targets varying from 4.0 to 6.0 mmol/l [2–4]. Levy et al. propose a 
lower glucose limit of 5 mmol/l with the catchphrase ‘stop at 5 and keep the inpatient alive’. 
Because one in every five inpatients with diabetes experiences a hypoglycaemic episode, 
there is no doubt that measures must be taken to minimize this potentially serious 
complication [5]. We agree that, for many if not all, inpatients with diabetes, a ‘floor of 4’ 
may be too low and thus contribute to potentially modifiable hypoglycaemia. We suggest that 
the current tools and how they are implemented (often suboptimally) by non-specialist staff 
on busy wards also contribute to the persistently high rates of inpatient hypoglycaemia and 
insulin errors. 
Regardless of the lower threshold glycaemic targets, our current inpatient diabetes tools cannot 
achieve and maintain precise glucose concentrations of 4.0 vs. 5.0 mmol/l. Current methods of 
inpatient diabetes treatment include variable rate intravenous insulin infusion (VRIII), 
subcutaneous insulin, oral medications and, to a lesser extent, continuous subcutaneous insulin 
infusion (CSII). VRIII is typically used in acute settings such as critical care, labour and 
delivery, surgery with prolonged fasting, diabetic ketoacidosis and acute decompensated 
diabetes. Based on hourly capillary glucose testing, the rate of intravenous insulin is adjusted by 
ward staff. This is invasive, resource intensive and by its nature, reactive. The VRIII allows for 
very little personalization and is managed by busy ward staff who may have limited diabetes 
training and many competing interests. The concern with VRIII as a tool in diabetes inpatient 
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management is echoed by the guidelines and the National Diabetes Inpatient Audit (NaDIA), 
which recommend use of VRIII only when clearly indicated [3,5]. 
Unfortunately, VRIII is the current gold standard for high-acuity clinical scenarios that require 
careful and quick insulin titration, but as a gold standard it is disappointing. 
At the upper glycaemic threshold, JBDS guidelines for the management of adults with diabetes 
undergoing surgery and elective procedures propose an acceptable blood glucose of up to 
12 mmol/l (target: 6–10 mmol/l) in the surgical population. For inpatients who are stable and in 
whom tight control is safely achieved, aiming for higher glycaemic targets may seem counter-
intuitive. In reality, the risk of impaired wound healing with higher glycaemic targets needs to 
be weighed against the possible increased risk of hypoglycaemia with tighter targets [6]. 
In the intrapartum management of diabetes, glycaemic targets are based in part on the rationale 
that maternal hyperglycaemia during this time may increase the risk of neonatal hypoglycaemia. 
It is beyond doubt that maternal hyperglycaemia during the second and third trimesters is clearly 
associated with fetal hyperinsulinaemia, neonatal hypoglycaemia and neonatal intensive care 
unit admission [7,8]. However, we completely agree that there are insufficient data supporting a 
clear association between short duration intrapartum hyperglycaemia and newborn 
hypoglycaemia [9]. Direct measurements of fetal intrapartum glucose are limited, but historical 
data suggest that the placenta prevents unlimited transport of glucose to the fetus during labour, 
regardless of the degree of maternal hyperglycaemia [10]. 
Pregnant women with Type 1 diabetes increasingly prefer to self-manage their glucose control 
during hospital admissions and may achieve effective inpatient glucose control using insulin 
pump or novel automated glucose-responsive closed-loop insulin delivery [11,12]. We 
recently reported preliminary data of closed-loop insulin delivery during labour and delivery 
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with an intrapartum glucose target of 3.5–7.8 mmol/l [12]. Women spend > 80% of time in 
target during the 24 h prior to delivery. Importantly, this tight glycaemic control was achieved 
with little time spent in hypoglycaemia. A ‘floor of either 4 or 5’ while using automated 
insulin delivery, especially in closely (and increasing continuously glucose monitored) labour 
and delivery units may be reasonable. However, without automated insulin delivery and with 
the current tight glycaemic targets during this period, maternal hypoglycaemia is far too 
common [9]. 
Outside labour and delivery, closed-loop insulin delivery has been shown to improve time-in-
target without increasing hypoglycaemia in inpatients with diabetes in critical care and hospital 
ward settings [13,14]. These studies also highlight suboptimal glucose control in standard 
inpatient care: 41% time spent in the target range of 5.6–10.0 mmol/l in hospital ward settings 
and 73% in the critical care setting using VRIII. The comparable time-in-target values using 
closed-loop insulin delivery were 66% and 92%, with negligible hypoglycaemia [13,14]. 
Our current tools often fall short of providing people with diabetes excellent care, especially 
inpatient care when glucose levels and insulin requirements fluctuate. It is our hope that 
automated insulin delivery will replace the need for VRIII and subcutaneous insulin dosing in a 
way that protects from inpatients from hypoglycaemia. Until then, inpatient diabetes 
management must continue to be an intricate balancing act; one that considers hypo- and 
hyperglycaemia, safety and resource use, guidelines and person-centred care, and the acuity and 
invasiveness of treatment. It is our hope that better tools will ultimately improve day-to-day 
glucose control in people with diabetes during admission to hospital. Until then, stopping at five 
to keep the in-patient alive may be the safest option. 
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